摘要
目的:研究重组人促红细胞生成素(rh-EPO)用药情况及相关影响因素,为临床合理用药提供依据。方法:采用前瞻性调查方法,逐日筛选、即时追踪2009年2～5月入住我院并使用rh-EPO病人用药情况,评价疗效并观察用药安全性及合理性。结果:233例中有效31.33%。治疗肾性贫血最多195例(83.69%),有效率为32.31%。对疗效有显著影响(P<0.05)的因素包括住院天数、慢性肾功能不全肾功能分期、用药前血红蛋白值以及是否输血。三个不同厂家产品的疗效差异无统计学意义。结论:RH-EPO治疗慢性肾功能不全患者的肾性贫血安全有效;其疗效与患者慢性肾功能不全分期、住院时间、用药前血红蛋白值等因素密切相关。
Objective ： To evaluate the effectiveness and safety of the therapy with recombinant human erythropoietin （rh-EPO） in inpatients and analyze its possible influence factors. Methods ： Data were collected from the Hospital Information System for anemia patients who received rh-EPO between February, 2009 and May, 2009 on a daily basis. Resuits： Out of the 233 patients included in the analysis, 73 cases （31.33%） were effective. 195 patients had renal anemia, and the average effective rate of these patients was 32.31%. The factors that could have significant effects were the stage of chronic renal failure, length of stay in hospital, hemoglobin level before treatment and red-blood-cell transfusion during treatment. There was no noteworthy difference between products from three companies. Conclusion：Published data suggested the gnaruteed clinical effectiveness and safety of rh-EPO. It is necessary for continued researches with larger samples to clarify the relation between the effectiveness and patients＇ other clinical pathology information.
出处
《药物流行病学杂志》
CAS
2010年第6期333-336,共4页
Chinese Journal of Pharmacoepidemiology
